Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Onconetix (ONCO) Accumulated Expenses (2023 - 2025)

Historic Accumulated Expenses for Onconetix (ONCO) over the last 3 years, with Q3 2025 value amounting to $476289.0.

  • Onconetix's Accumulated Expenses fell 6439.39% to $476289.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $476289.0, marking a year-over-year decrease of 6439.39%. This contributed to the annual value of $888988.0 for FY2024, which is 167797.6% up from last year.
  • Onconetix's Accumulated Expenses amounted to $476289.0 in Q3 2025, which was down 6439.39% from $894986.0 recorded in Q2 2025.
  • Onconetix's 5-year Accumulated Expenses high stood at $1.9 million for Q1 2024, and its period low was $50000.0 during Q4 2023.
  • Its 3-year average for Accumulated Expenses is $1.1 million, with a median of $1.3 million in 2023.
  • As far as peak fluctuations go, Onconetix's Accumulated Expenses soared by 167797.6% in 2024, and later tumbled by 6439.39% in 2025.
  • Over the past 3 years, Onconetix's Accumulated Expenses (Quarter) stood at $50000.0 in 2023, then soared by 1677.98% to $888988.0 in 2024, then crashed by 46.42% to $476289.0 in 2025.
  • Its Accumulated Expenses stands at $476289.0 for Q3 2025, versus $894986.0 for Q2 2025 and $1.2 million for Q1 2025.